New paper in Biomedicine & Pharmacotherapy
16 04 2026
Category: Publications
Check out our new paper in the journal Biomedicine & Pharmacotherapy. In a collaborative study researchers Dr Adrian Konopko, Dr Katarzyna Sęktas, and Prof. Grzegorz Litwinienko from the Faculty of Chemistry, University of Warsaw (UW), alongside Alicja Targońska and Prof. Anna Bielak-Zmijewska from the Nencki Institute of Experimental Biology and Prof. Riccardo Amorati from the University of Bologna, have developed a hybrid molecule protecting against the cellular aging process.
A covalent resveratrol-nitroxide conjugate protects against oxidative stress-induced cellular senescence
Biomedicine & Pharmacotherapy, 2026, 198, 119357, DOI: 10.1016/j.
Cellular senescence, largely driven by excess reactive oxygen species (ROS), is a major contributor to organismal aging, yet current treatments often suffer from low effectiveness due to poor bioavailability. To address this, the team synthesized a novel compound named H3, which covalently links the natural antioxidant Resveratrol (RSV) with the superoxide dismutase mimetic TEMPO. The study demonstrated that H3 acts as a potent radical-trapping antioxidant that significantly outperforms Resveratrol, TEMPO, or even a mixture of both in preserving cell health. In human dermal fibroblasts, H3 was found to be non-cytotoxic and highly effective at reducing hallmarks of senescence, allowing cells to maintain their ability to replicate and divide. Beyond simply neutralizing free radicals, H3 actively supports the cell’s internal machinery; under oxidative stress, it maintains critical antioxidant enzymes like SOD1, CAT, and HO-1. Furthermore, it upregulates essential proteins for DNA repair and genome stability, including Lamin B1, PARP, SirT1, and SirT6. By combining direct chemical protection with the ability to influence genetic expression, H3 emerges as a powerful new anti-senescent agent with the potential to redefine how we treat age-related cellular decline.